ABC | Volume 114, Nº2, February 2020

Editorial Mesquita et al. Nuclear Cardiology in 2020 – Perspectives of the new SBC Guideline Arq Bras Cardiol. 2020; 114(2):196-198 1. Mastrocola LE, AmorimBJ, Vitola JV, Brandão SCS, Grossman GB, Lima RSL et al. Atualização da Diretriz Brasileira de Cardiologia Nuclear – 2020. Arq Bras Cardiol. 2020; 114(2):325-429. 2. Stone GW, Hochman JS,Williams DO, BodenWE, Ferguson TB, Harrington RA, et al. Medical therapy with versus without revascularization in stable patients with moderate and severe ischemia the case for community equipoise. J Am Coll Cardiol. 2016; 67(1):81-99. 3. Boden W, O’Rourke R, Teo K, Hartigan, Maron D, Kostuk E., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):503-1. 4. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019 Aug 31;pii:ehz425. (Epub ahead of print) 5. Reynolds HR, Picard MH, Hochman JS. Does ischemia burden in stable coronary artery disease effectively identify revascularization candidates? Circ Cardiovasc Imaging. 2015;8(5):1-8. 6. Maron DJ, Hochman JS, Brien SMO, Reynolds R, BodenWE, Stone GW, et al. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: rationale and design. AmHeart J. 2018;201:124-35 7. Habib G, Lancelloti P, Antunes M , Bongiorni MG, Casalta JP, Del Zotti et al. et al. Guidelines for the management of infective endocarditis. Eur Heart J. 2015;36(44):3075-123. 8. Bois JP, Muser D, Chareonthaitawee P. PET/CT Evaluation of Cardiac Sarcoidosis. PET Clin. 2019;14(2):223-32. 9. Ramirez R, Trivieri M, Fayad ZA, Ahmadi A, Narula J, Argulian E. Advanced imaging in cardiac sarcoidosis. J Nucl Med. 2019;60(7):892-8. 10. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-12. 11. Treglia G, Glaudemans AWJM, Bertagna F, Hazenbeg BPC, Erba P, Giubbini R,etal.Diagnosticaccuracyofbonescintigraphy intheassessmentofcardiac transthyretin-related amyloidosis: a bivariatemeta-analysis. Eur J Nucl Med Mol Imaging. 2018;45(11):1945-55. 12. Narula J, Gerson M, Thomas GS, Cerqueira MD, Jacobson AF. 123 I-MIBG imaging for prediction of mortality and potentially fatal events in heart failure: The ADMIRE-HFX Study. J Nucl Med. 2015;56(7):1011-8. 13. Sabra MMM, Costa FS, de Azevedo JC, Mesquita CT, Verberne HJ. Myocardial perfusion scintigraphy during chest pain: An atypical presentation of takotsubo cardiomyopathy? J Nucl Cardiol. 2019;26(2):674-6. 14. Schuijf JD, Matheson MB, Ostovaneh MSMR. Ischemia and no obstructive stenosis (INOCA) at CT angiography, ct myocardial perfusion, invasive coronary. Radiology. 2019;(5):1-13. 15. BaireyMerz CN, Pepine CJ, WalshMN, Fleg JL. Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade. Circulation. 2017;135(11):1075-92. 16. Agostini D, Roule V, Nganoa C, Roth N, Baavour R, Parienti JJ et al. First validation of myocardial flow reserve assessed by dynamic 99mTc-sestamibi CZT-SPECT camera: head to head comparison with 15O-water PET and fractional flow reserve in patients with suspected coronary artery disease. TheWATERDAY study. Eur J Nucl MedMol Imaging. 2018; 45(7):1079-90. 17. Siqueira FPR, Mesquita CT, Santos AAS, Nacif MS. Relationship between calcium score and myocardial scintigraphy in the diagnosis of coronary disease. Arq Bras Cardiol . 2016;107(4):365–74. References This is an open-access article distributed under the terms of the Creative Commons Attribution License 198